menu ☰
menu ˟

FDA accepts supplemental application for Imbruvica for treatment of chronic GVHD

05 Apr 2017
The FDA accepted for review a supplemental new drug application for ibrutinib for the treatment of patients with chronic graft-versus-host disease who failed at least one prior line of systemic therapy, according to the drug’s manufacturers.If appr...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.